Morgan Stanley’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,672,825
| Closed | -$9.48M | – | 8423 |
|
|
2025
Q3 | $9.48M | Sell |
1,672,825
-475,061
| -22% | -$2.43M | ﹤0.01% | 3603 |
|
|
2025
Q2 | $8.18M | Buy |
2,147,886
+261,745
| +14% | +$813K | ﹤0.01% | 3622 |
|
|
2025
Q1 | $4.96M | Sell |
1,886,141
-23,947
| -1% | -$78K | ﹤0.01% | 3937 |
|
|
2024
Q4 | $6.76M | Buy |
1,910,088
+1,577,434
| +474% | +$6.04M | ﹤0.01% | 3730 |
|
|
2024
Q3 | $1.52M | Buy |
332,654
+111,363
| +50% | +$539K | ﹤0.01% | 4804 |
|
|
2024
Q2 | $963K | Buy |
221,291
+40,571
| +22% | +$178K | ﹤0.01% | 4983 |
|
|
2024
Q1 | $907K | Sell |
180,720
-17,866
| -9% | -$100K | ﹤0.01% | 5009 |
|
|
2023
Q4 | $1.25M | Sell |
198,586
-936,993
| -83% | -$5.37M | ﹤0.01% | 4801 |
|
|
2023
Q3 | $8.09M | Sell |
1,135,579
-25,786
| -2% | -$203K | ﹤0.01% | 3318 |
|
|
2023
Q2 | $11.8M | Sell |
1,161,365
-6,196
| -0.5% | -$64.7K | ﹤0.01% | 3012 |
|
|
2023
Q1 | $10.6M | Buy |
1,167,561
+1,018,583
| +684% | +$7.46M | ﹤0.01% | 3093 |
|
|
2022
Q4 | $1.07M | Buy |
148,978
+55,689
| +60% | +$340K | ﹤0.01% | 4836 |
|
|
2022
Q3 | $608K | Sell |
93,289
-2,414
| -3% | -$12.9K | ﹤0.01% | 5167 |
|
|
2022
Q2 | $461K | Buy |
95,703
+9,118
| +11% | +$45.1K | ﹤0.01% | 5461 |
|
|
2022
Q1 | $492K | Buy |
86,585
+11,750
| +16% | +$57.7K | ﹤0.01% | 5408 |
|
|
2021
Q4 | $375K | Buy |
74,835
+4,742
| +7% | +$26.1K | ﹤0.01% | 5717 |
|
|
2021
Q3 | $465K | Buy |
70,093
+8,929
| +15% | +$53.4K | ﹤0.01% | 5544 |
|
|
2021
Q2 | $374K | Buy |
61,164
+6,875
| +13% | +$41.5K | ﹤0.01% | 5701 |
|
|
2021
Q1 | $361K | Buy |
54,289
+16,748
| +45% | +$115K | ﹤0.01% | 5334 |
|
|
2020
Q4 | $199K | Buy |
37,541
+4,838
| +15% | +$37.9K | ﹤0.01% | 5591 |
|
|
2020
Q3 | $244K | Sell |
32,703
-5,606
| -15% | -$43.8K | ﹤0.01% | 5006 |
|
|
2020
Q2 | $282K | Sell |
38,309
-2,193
| -5% | -$19.3K | ﹤0.01% | 4905 |
|
|
2020
Q1 | $300K | Sell |
40,502
-4,371
| -10% | -$31.7K | ﹤0.01% | 4670 |
|
|
2019
Q4 | $254K | Sell |
44,873
-5,051
| -10% | -$25.8K | ﹤0.01% | 5308 |
|
|
2019
Q3 | $293K | Buy |
49,924
+36,291
| +266% | +$205K | ﹤0.01% | 4944 |
|
|
2019
Q2 | $43K | Buy |
13,633
+3,306
| +32% | +$10.8K | ﹤0.01% | 5670 |
|
|
2019
Q1 | $31K | Sell |
10,327
-12,172
| -54% | -$41.8K | ﹤0.01% | 5866 |
|
|
2018
Q4 | $84K | Sell |
22,499
-1,108
| -5% | -$5.21K | ﹤0.01% | 5613 |
|
|
2018
Q3 | $138K | Sell |
23,607
-52,361
| -69% | -$267K | ﹤0.01% | 5592 |
|
|
2018
Q2 | $430K | Buy |
75,968
+52,708
| +227% | +$542K | ﹤0.01% | 5198 |
|
|
2018
Q1 | $288K | Buy |
23,260
+18,195
| +359% | +$245K | ﹤0.01% | 5305 |
|
|
2017
Q4 | $61K | Buy |
+5,065
| New | +$71.5K | ﹤0.01% | 5772 |
|
Morgan Stanley's SCPH Position: Q4 2025 in Review
Morgan Stanley sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 1,672,825 shares — an estimated $9.48M sold.
Morgan Stanley first reported a position in SCPH in Q4 2017 and held it in 32 quarters. The position peaked at $11.8M in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Morgan Stanley reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 1,672,825 scPharmaceuticals shares in Q4 2025, an estimated $9.48M.
- Morgan Stanley first reported a position in scPharmaceuticals in Q4 2017 and held it in 32 quarters.
- Morgan Stanley's scPharmaceuticals position peaked at $11.8M in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.